Terms: = Sarcomas AND PAX3, MGC120382, 5077, ENSG00000135903, CDHS, MGC120383, HUP2, P23760, WS1, MGC120384, MGC134778, MGC120381 AND Prognosis
73 results:
1. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Martin-Giacalone BA; Li H; Scheurer ME; Casey DL; Dugan-Perez S; Marquez-Do DA; Muzny D; Gibbs RA; Barkauskas DA; Hall D; Stewart DR; Schiffman JD; McEvoy MT; Khan J; Malkin D; Linardic CM; Crompton BD; Shern JF; Skapek SX; Venkatramani R; Hawkins DS; Sabo A; Plon SE; Lupo PJ
JAMA Netw Open; 2024 Mar; 7(3):e244170. PubMed ID: 38546643
[TBL] [Abstract] [Full Text] [Related]
2. Treatment of nasolabial fold rhabdomyosarcoma in children: A single-institution experience.
Zhang G; Sun N; Ni X; Su Y; He L; Liu Z; Zhang J; Li Y; Zhang X; Liu Q; Liu Z; Li X; Mei L; Liu Y; Ji T; Wang S
Head Neck; 2024 Apr; 46(4):905-914. PubMed ID: 38214480
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract] [Full Text] [Related]
4. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
[TBL] [Abstract] [Full Text] [Related]
5. Piperacetazine Directly Binds to the pax3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
[TBL] [Abstract] [Full Text] [Related]
6. Extremity Rhabdomyosarcoma-An Integrated Clinicopathologic and Genomic Study to Improve Risk Stratification.
de Traux de Wardin H; Xu B; Dermawan JK; Smith MH; Wolden SL; Antonescu CR; Wexler LH
JCO Precis Oncol; 2023 Jun; 7(1):e2200705. PubMed ID: 37315267
[TBL] [Abstract] [Full Text] [Related]
7. Rhabdomyosarcomas are oncogene addicted to the activation of AVIL.
Xie Z; Janczyk PL; Shi X; Wang Q; Singh S; Cornelison R; Xu J; Mandell JW; Barr FG; Li H
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2118048119. PubMed ID: 37146302
[TBL] [Abstract] [Full Text] [Related]
8. [Alveolar rhabdomyosarcoma: novel surrogate markers associated with oncogenic translocation].
Tarakanova AV; Sharlay AS; Konovalov DM
Arkh Patol; 2023; 85(1):10-15. PubMed ID: 36785957
[TBL] [Abstract] [Full Text] [Related]
9. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
[TBL] [Abstract] [Full Text] [Related]
10. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
[TBL] [Abstract] [Full Text] [Related]
11. Metastatic rhabdomyosarcoma with exclusive distant lymph node involvement: A European Pediatric Soft tissue sarcoma Study Group (EpSSG) report.
Mercolini F; Merks JHM; Minard-Colin V; Cameron A; van Scheltinga SEJT; Sher O; Fichera G; Orbach D; Glosli H; Coppadoro B; Gallego S; Chisholm JC; Bisogno G
Pediatr Blood Cancer; 2023 Mar; 70(3):e30143. PubMed ID: 36519598
[TBL] [Abstract] [Full Text] [Related]
12. Biphenotypic sinonasal sarcoma - a case report.
Bartoš V; Rác P; Skálová A
Klin Onkol; 2022; 35(5):402-406. PubMed ID: 36443095
[TBL] [Abstract] [Full Text] [Related]
13. Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness.
Poli E; Barbon V; Lucchetta S; Cattelan M; Santoro L; Zin A; Milano GM; Zanetti I; Bisogno G; Bonvini P
Oncoimmunology; 2022; 11(1):2096349. PubMed ID: 35813575
[TBL] [Abstract] [Full Text] [Related]
14. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking pax3-FOXO1 and PAX7-FOXO1].
Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
[TBL] [Abstract] [Full Text] [Related]
15. High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma.
Generali M; Satheesha S; Bode PK; Wanner D; Schäfer BW; Casanova EA
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573355
[TBL] [Abstract] [Full Text] [Related]
16. Reduced B7-H3 expression by pax3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma.
Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155
[TBL] [Abstract] [Full Text] [Related]
17. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence.
Li JJ; Kovach AR; DeMonia M; Slemmons KK; Oristian KM; Chen C; Linardic CM
Sci Rep; 2021 Aug; 11(1):16505. PubMed ID: 34389744
[TBL] [Abstract] [Full Text] [Related]
18. A Review of Effusion Cytomorphology of Small Round Cell Tumors.
Han LM; VandenBussche CJ; Abildtrup M; Chandra A; Vohra P
Acta Cytol; 2022; 66(4):336-346. PubMed ID: 34218227
[TBL] [Abstract] [Full Text] [Related]
19. FOXF1 is required for the oncogenic properties of pax3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract] [Full Text] [Related]
20. Rhabdomyosarcoma: From Obscurity to Clarity in Diagnosis … But With Ongoing Challenges in Management: The Farber-Landing Lecture of 2020.
Parham DM; Giannikopoulos P
Pediatr Dev Pathol; 2021; 24(2):87-95. PubMed ID: 33439112
[TBL] [Abstract] [Full Text] [Related]
[Next]
